Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal

Neuropharmacology

Volumn 37, Issue 8, 1998, Pages 1007-1017

  Grasing, Kenneth ^a   Ghosh, Suchandra ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

4 Aminopyridine; Amphetamine; Cocaine; Dopamine; Morphine; Nucleus accumbens; Selegiline; Stress immobility; Striatum; Withdrawal syndrome

Indexed keywords

4 AMINOPYRIDINE; AMPHETAMINE; COCAINE; DOPAMINE; MORPHINE; SELEGILINE;

ABSTINENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG WITHDRAWAL; IMMOBILIZATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; STRESS; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

ANIMALS; DOPAMINE; MALE; MORPHINE; RATS; RATS, WISTAR; RESTRAINT, PHYSICAL; SELEGILINE; STRESS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0031666671     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00093-8     Document Type: Article

References (62)

1. Acquas, E., Di Chiara, G., 1992. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J. Neurochem. 58, 1620-1625.
2. Acquas, E., Carboni, E., Di Chiara, G., 1991. Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur. J. Pharmacol. 193, 133-134.
3. Ahtee, L., Attila, L.M.J., 1987. Cerebral monoamine neurotransmitters in opioid withdrawal and dependence. Med. Biol. 65, 113-119.
4. Airio, J., Attila, M., Liekola-Pelho, T., Ahtee, L., 1994. Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine. Naunyn-Schmiedebergs Arch. Pharmacol. 350, 548-554.
5. Akera, T., Brody, T.M., 1968. The addiction cycle to narcotics in the rat and its relation to catecholamines. Biochem. Pharmacol. 17, 675-688.
6. Attila, L.M.J., Ahtee, L., 1984. Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 327, 201-207.
7. Carrillo, M.C., Kitani, K., Kanai, S., Sato, Y., Ivy, G.O., 1992. The ability of (-) deprenyl to increase superoxide dismutase activites in the rat is tissue and brain region selective. Life Sci. 50, 1985-1992.
8. Chiueh, C.C., Wu, R.M., Mohanakumar, K.P., Sternberger, L.M., Krishna, G., Obata, T., Murphy, D.L., 1994. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. New York Acad. Sci. 738, 25-36.
9. Church, W.H., Justice, J.B., Byrd, L.D., 1987. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine, and benztropine. Eur. J. Pharmacol. 139, 345-348.
10. Crippens, D., Robinson, T.E., 1994. Withdrawal from morphine or amphetamine: different effects on dopamine in the ventral-medial striatum studied with microdialysis. Brain Res. 650, 56-62.
11. Devoize, J.L., Rigal, F., Eschalier, A., Trolese, J.F., Renoux, M., 1984. Influence of naloxone on antidepressant drug effects in the forced swimming test in mice. Psychopharmacology 84, 71-75.
12. Diana, M., Pistis, M., Muntoni, A., Gessa, G., 1995. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J. Pharmacol. Exp. Ther. 272, 781-785.
13. Diana, M., Pistis, M., Muntoni, A., Gessa, G., 1996. Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Neuroscience 71, 411-415.
14. Di Chiara, G., Imperato, A., 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85, 5274-5278.
15. Fallon, J.H., 1988. Topographic organization of ascending dopaminergic projections. Ann. New York Acad. Sci. 537, 1-9.
16. Fielding, S., Szewczak, M.R., 1984. Pharmacology of nomifensine: a review of animal studies. J. Clin. Psychiatry 45, 12-20.
17. Finnegan, K.T., Skratt, J.J., Irwin, I., DeLanney, L.E., Langsten, J.W., 1990. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur. J. Pharmacol. 184, 119-126.
18. Ghosh, S., Patel, A.H., Cousins, M., Grasing, K., 1998. Different effects of opiate withdrawal on dopamine turnover, uptake, and release in the striatum and nucleus accumbens. Neurochem. Res. (in press).
19. Grasing, K., Bills, D., Ghosh, S., Schlussman, S., Patel, A.H., Woodward, JJ., 1997. Opiate modulation of striatal dopamine and hippocampal norepinephrine release following morphine withdrawal. Neurochem. Res. 22, 239-248.
20. Haberny, K.A., Walsh, S.L., Ginn, D.H., Wilkins, J.N., Garner, J.E., Setoda, D., Bigelow, G.E., 1995. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. 39, 55-62.
21. Harris, G.C., Aston-Jones, G., 1994. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 371, 155-157.
22. Heinonen, E., Lammintausta, R., 1991. A review of the pharmacology of selegiline. Acta Neurol. Scand. 84 (suppl 136), 44-59.
23. Howes, J.F., 1981. A simple, reliable method for predicting the physical dependence liability of narcotic antagonist analgesics in the rat. Pharmacol. Biochem. Behav. 14, 689-692.
24. Johnson, D.W., Glick, S.D., 1994. Handling and/or saline injections alter basal and morphine-evoked changes in dopamine metabolites in the striatum and nucleus accumbens of rats. Pharmacol. Biochem. Behav. 47, 765-768.
25. Kampman, K., Volpicelli, J.R., Alterman, A., Cornish, J., Weinrieb, R., Epperson, L., Sparkman, T., O'Brien, C.P., 1996. Amantadine in the early treatment of cocaine dependence: a double blind, placebo-controlled trial. Drug Alcohol Depend. 41, 25-33.
26. Kerecsen, L., Kalasz, H., Knoll, J., 1986. (-)Deprenyl enhances dopamine release from isolated striatal preparations of rats following chronic pretreament. In: Knoll, J., Kelemen, K. (Eds.), Advances in Pharmacological Research and Practice. Pergamon Press, London, pp. 27-33.
27. Kishioka, S., Nishida, S., Fukunaga, Y., Yamamoto, H., 1994. Quantitative properties of plasma corticosterone elevation induced by naloxone-precipitated withdrawal in morphine-dependent rats. Jpn. J. Pharmacol. 66, 257-263.
28. Knoll, J., Miklya, I., 1994. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch. Int. Pharmacodyn. Ther. 328, 1-15.
29. Knollema, S., Aukema, W., Hom, H., Korf, J., Ter Horst, G.J., 1995. L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 26, 1883-1887.
30. Koe, B.K., 1976. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp. Ther. 199, 649-661.
31. Kuhar, M.J., Pilotte, N.S., 1996. Neurochemical changes in cocaine withdrawal. Trends Pharmacol. Sci. 17, 260-264.
32. Lange, K.W., Riederer, P., Youdim, M.B.H., 1994. Biochemical actions of 1-deprenyl (selegiline). Clin. Pharmacol. Ther. 56, 734-741.
33. Little, K.Y., Patel, U.N., Clark, T.B., Butts, J.D., 1996. Alteration of brain dopamine and serotonin levels in cocaine users: a preliminary report. Am. J. Psychiatry 153, 1216-1218.
34. Molina, V.A., Heyser, C.J., Spear, L.P., 1994. Chronic variable stress or chronic morphine facilitates immobility in a forced swim test: reversal by naloxone. Psychopharmacology 114, 433-440.
35. Okuda, C., Segal, D.S., Kuczenski, R., 1992. Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. Pharmacol. Biochem. Behav. 43, 1075-1080.
36. Parker, E.M., Cubeddu, L.X., 1988. Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245, 199-210.
37. Paterson, I.A., Barber, A.J., Gelowitz, D.L., Voll, C., 1997. (-) Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci. Biobehav. Rev. 21, 181-186.
38. Paulson, P.E., Robinson, T.E., 1996. Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum: analysis of circadian patterns using automated on-line microdialysis. Neuropsychopharmacology 14, 325-337.
39. Pifl, C., Drobny, H., Reither, H., Hornykiewicz, O., Singer, E.A., 1995. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368-373.
40. Porsolt, R.D., Bertin, A., Blavet, N., Deniel, M., Jalfre, M., 1979. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol. 57, 201-210.
41. Pozzi, L., Trabace, L., Invernizzi, R., Samanin, R., 1995. Intranigral GR-113808, a selective 5-HT receptor antagonist, attenuates morphine-stimulated dopamine release in the rat striatum. Brain Res. 692, 265-268.
42. Rogawski, M.A., Barker, J.L., 1983. Effects of 4-aminopyridine on calcium action potentials and calcium current under voltage clamp in spinal neurons. Brain Res. 280, 180-185.
43. Rossetti, Z.L., Hmaidan, Y., Gessa, G., 1992a. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 221, 227-234.
44. Rossetti, Z.L., Melis, F., Carboni, S., Gessa, G.L., 1992b. Dramatic depletion of mesolimbic extracellular dopamine after withdrawal from morphine, alcohol or cocaine: a common neurochemical substrate for drug dependence. Ann. New York Acad. Sci. 654, 513-516.
45. Salo, P.T., Tatton, W.G., 1992. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31, 394-400.
46. 3H-Ro19-6327 in vitro; localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 12, 1977-1999.
47. Schneider, L.S., Tariot, P.N., Goldstein, B., 1994. Therapy with 1-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 56, 750-756.
48. Spanagel, R., Almeida, O.P., Shippenberg, T.S., 1993. Long lasting changes in morphine-induced mesolimbic dopamine release after chronic morphine exposure. Synapse 14, 243-245.
49. Spanagel, R., Almeida, O.F., Bartl, C., Shippenberg, T.S., 1994. Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology 115, 121-127.
50. Sprague, J.E., Nichols, D.E., 1995. The monoamine oxidase-b inhibitor 1-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667-673.
51. Stamford, J.A., 1995. Voltammetry in brain slices. In: Schurr, A., Rigor, B.M. (Eds.), Brain Slices in Basic and Clinical Research. CRC Press, Boca Raton, pp. 65-88.
52. Stenstrom, A., Hardy, J., Oreland, L., 1987. Intra- and extra-dopamine-synaptosomal localization of monoamine oxidase activity in striatal homogenates from four species. Biochem. Pharmacol. 36, 2931-2935.
53. Stolerman, I.P., Johnson, C.A., Bunker, P., Jarvik, M.P., 1975. Weight loss and shock-elicited aggression as indices of morphine abstinence in rats. Psychopharmacologia 45, 157-161.
54. Tatton, W.G., Greenwood, C.E., 1991. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666-672.
55. Tien Ril, H.K.G.T., De Vries, T.J., Wardeh, G., Hogenboom, P., Mulder, A.H., Schoffelmeer, A.N.M., 1993. Long-lasting reciprocal changes in striatal dopamine and acetylcholine release upon morphine withdrawal. Eur. J. Pharmacol. 235, 321-322.
56. Tjon, G.H.K., De Vries, T.J., Ronken, P., Hogenboom, P., Wardeh, G., Mulder, A.H., Schoffelmeer, A.N.M., 1994. Repeated and chronic morphine administration causes differential long-lasting changes in dopaminergic neurotransmission in rat striatum without changing its delta and kappa opioid receptor regulation. Eur. J. Pharmacol. 252, 205-212.
57. Volkow, N.D., 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch. Gen. Psychiatry 52, 456-463.
58. Volkow, N.D., Fowler, J.S., Wang, G.J., Hitzemann, R., Logan, J., Schlyer, D.J., Dewey, S.L., Wolf, A.P., 1993. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14, 169-177.
59. Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Gatley, S.J., Hitzemann, R., Chen, A.D., Dewey, S.L., Pappas, N., 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386, 830-833.
60. Wieland, S., Lucki, I., 1990. Antidepressant-like activity of 5-HT-1A agonists measured with the forced swim test. Psychopharmacology 101, 497-504.
61. Woodward, J.J., Harms, J., 1992. Potentiation of N-methyl-D-aspartate stimulated dopamine release from rat brain slices by aluminum fluoride and carbechol. J. Neurochem. 58, 1547-1554.
62. Youdim, M.B., Finberg, J.P.M., 1991. New directions in monoamine oxidase A and B: selective inhibitors and substrates. Biochem. Pharmacol. 41, 155-162.